Skip to main content
Erschienen in:

01.08.2019 | Original Article – Cancer Research

Protein expression of close homologue of L1 (CHL1) is a marker for overall survival in non-small cell lung cancer (NSCLC)

verfasst von: Jenny Hötzel, Nathaniel Melling, Julia Müller, Adam Polonski, Gerrit Wolters-Eisfeld, Jakob R. Izbicki, Karl-F. Karstens, Michael Tachezy

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

The cell adhesion molecule close homologue of L1 (CHL1) is a potential tumour suppressor and was recently detected in non-small cell lung cancer (NSCLC) specimens. The expression pattern, prognostic, and functional role of CHL1 in NSCLCs is unknown.

Methods

We evaluated the protein expression of CHL1 by immunohistochemistry in 2161 NSCLC patients based on a tissue microarray. The results were correlated with clinical, histopathological, and patient survival data (Chi square test, t test, and log-rank test, respectively). A multivariate analysis (Cox regression) was performed to validate its impact on patients’ survival.

Results

CHL1 was expressed in NSCLC patients and was significantly overexpressed in lung adenocarcinomas and squamous cell carcinomas compared to neuroendocrine and large cell carcinomas of the lung (p < 0.001). CHL1 expression was associated with the T stage in adenocarcinomas (p = 0.011) and with metastatic lymph node status and UICC stage in squamous cell carcinomas (p = 0.034 and p = 0.035, respectively). Increased CHL1 expression was associated with improved survival in univariate (p = 0.031) and multivariate analyses (odds ratio 0.797, 95% confidence interval 0.677–0.939, p = 0.007).

Conclusion

The prognostic significance of CHL1 makes it a potential prognostic and therapeutic target and underlines its role as a tumour suppressor. Further validation studies and functional analyses are needed to investigate its potential role in tumourigenesis and dissemination.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Conacci-Sorrell ME, Ben-Yedidia T, Shtutman M, Feinstein E, Einat P, Ben-Ze’ev A (2002) Nr-CAM is a target gene of the beta-catenin/LEF-1 pathway in melanoma and colon cancer and its expression enhances motility and confers tumorigenesis. Genes Dev. 16(16):2058–2072CrossRefPubMedPubMedCentral Conacci-Sorrell ME, Ben-Yedidia T, Shtutman M, Feinstein E, Einat P, Ben-Ze’ev A (2002) Nr-CAM is a target gene of the beta-catenin/LEF-1 pathway in melanoma and colon cancer and its expression enhances motility and confers tumorigenesis. Genes Dev. 16(16):2058–2072CrossRefPubMedPubMedCentral
Zurück zum Zitat Dancau A-M, Simon R, Mirlacher M, Sauter G (2016) Tissue microarrays. Methods Mol Biol Clifton NJ. 1381:53–65CrossRef Dancau A-M, Simon R, Mirlacher M, Sauter G (2016) Tissue microarrays. Methods Mol Biol Clifton NJ. 1381:53–65CrossRef
Zurück zum Zitat Frints SGM, Marynen P, Hartmann D, Fryns J-P, Steyaert J, Schachner M et al (2003) CALL interrupted in a patient with non-specific mental retardation: gene dosage-dependent alteration of murine brain development and behavior. Hum Mol Genet 12(13):1463–1474CrossRefPubMed Frints SGM, Marynen P, Hartmann D, Fryns J-P, Steyaert J, Schachner M et al (2003) CALL interrupted in a patient with non-specific mental retardation: gene dosage-dependent alteration of murine brain development and behavior. Hum Mol Genet 12(13):1463–1474CrossRefPubMed
Zurück zum Zitat Górka B, Skubis-Zegadło J, Mikula M, Bardadin K, Paliczka E, Czarnocka B (2007) NrCAM, a neuronal system cell-adhesion molecule, is induced in papillary thyroid carcinomas. Br J Cancer 97(4):531–538CrossRefPubMedPubMedCentral Górka B, Skubis-Zegadło J, Mikula M, Bardadin K, Paliczka E, Czarnocka B (2007) NrCAM, a neuronal system cell-adhesion molecule, is induced in papillary thyroid carcinomas. Br J Cancer 97(4):531–538CrossRefPubMedPubMedCentral
Zurück zum Zitat He L-H, Ma Q, Shi Y-H, Ge J, Zhao H-M, Li S-F et al (2013) CHL1 is involved in human breast tumorigenesis and progression. Biochem Biophys Res Commun 438(2):433–438CrossRefPubMed He L-H, Ma Q, Shi Y-H, Ge J, Zhao H-M, Li S-F et al (2013) CHL1 is involved in human breast tumorigenesis and progression. Biochem Biophys Res Commun 438(2):433–438CrossRefPubMed
Zurück zum Zitat Klat J, Mladenka A, Dvorackova J, Bajsova S, Simetka O (2019) L1CAM as a negative prognostic factor in endometrioid endometrial adenocarcinoma FIGO stage IA-IB. Anticancer Res 39(1):421–424CrossRefPubMed Klat J, Mladenka A, Dvorackova J, Bajsova S, Simetka O (2019) L1CAM as a negative prognostic factor in endometrioid endometrial adenocarcinoma FIGO stage IA-IB. Anticancer Res 39(1):421–424CrossRefPubMed
Zurück zum Zitat Kotani N, Ida Y, Nakano T, Sato I, Kuwahara R, Yamaguchi A et al (2018) Tumor-dependent secretion of close homolog of L1 results in elevation of its circulating level in mouse model for human lung tumor. Biochem Biophys Res Commun. 501(4):982–987CrossRefPubMed Kotani N, Ida Y, Nakano T, Sato I, Kuwahara R, Yamaguchi A et al (2018) Tumor-dependent secretion of close homolog of L1 results in elevation of its circulating level in mouse model for human lung tumor. Biochem Biophys Res Commun. 501(4):982–987CrossRefPubMed
Zurück zum Zitat Lo Russo G, Imbimbo M, Corrao G, Proto C, Signorelli D, Vitali M et al (2017) Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases. Oncotarget. 8(35):59889–59900CrossRefPubMedPubMedCentral Lo Russo G, Imbimbo M, Corrao G, Proto C, Signorelli D, Vitali M et al (2017) Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases. Oncotarget. 8(35):59889–59900CrossRefPubMedPubMedCentral
Zurück zum Zitat Martín-Sánchez E, Mendaza S, Ulazia-Garmendia A, Monreal-Santesteban I, Blanco-Luquin I, Córdoba A et al (2017) CHL1 hypermethylation as a potential biomarker of poor prognosis in breast cancer. Oncotarget. 8(9):15789–15801CrossRefPubMedPubMedCentral Martín-Sánchez E, Mendaza S, Ulazia-Garmendia A, Monreal-Santesteban I, Blanco-Luquin I, Córdoba A et al (2017) CHL1 hypermethylation as a potential biomarker of poor prognosis in breast cancer. Oncotarget. 8(9):15789–15801CrossRefPubMedPubMedCentral
Zurück zum Zitat Naus S, Richter M, Wildeboer D, Moss M, Schachner M, Bartsch JW (2004) Ectodomain shedding of the neural recognition molecule CHL1 by the metalloprotease-disintegrin ADAM8 promotes neurite outgrowth and suppresses neuronal cell death. J Biol Chem 279(16):16083–16090CrossRefPubMed Naus S, Richter M, Wildeboer D, Moss M, Schachner M, Bartsch JW (2004) Ectodomain shedding of the neural recognition molecule CHL1 by the metalloprotease-disintegrin ADAM8 promotes neurite outgrowth and suppresses neuronal cell death. J Biol Chem 279(16):16083–16090CrossRefPubMed
Zurück zum Zitat Ognibene M, Pagnan G, Marimpietri D, Cangelosi D, Cilli M, Benedetti MC et al (2018) CHL1 gene acts as a tumor suppressor in human neuroblastoma. Oncotarget. 9(40):25903–25921CrossRefPubMedPubMedCentral Ognibene M, Pagnan G, Marimpietri D, Cangelosi D, Cilli M, Benedetti MC et al (2018) CHL1 gene acts as a tumor suppressor in human neuroblastoma. Oncotarget. 9(40):25903–25921CrossRefPubMedPubMedCentral
Zurück zum Zitat Raveh S, Gavert N, Ben-Ze’ev A (2009) L1 cell adhesion molecule (L1CAM) in invasive tumors. Cancer Lett. 282(2):137–145CrossRefPubMed Raveh S, Gavert N, Ben-Ze’ev A (2009) L1 cell adhesion molecule (L1CAM) in invasive tumors. Cancer Lett. 282(2):137–145CrossRefPubMed
Zurück zum Zitat Reck M, Popat S, Reinmuth N, De Ruysscher D, Kerr KM, Peters S et al (2014) Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 25(Suppl 3):iii27–iii39CrossRef Reck M, Popat S, Reinmuth N, De Ruysscher D, Kerr KM, Peters S et al (2014) Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 25(Suppl 3):iii27–iii39CrossRef
Zurück zum Zitat Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P et al (2000) Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24(3):227–235CrossRefPubMed Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P et al (2000) Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24(3):227–235CrossRefPubMed
Zurück zum Zitat Sakurai K, Migita O, Toru M, Arinami T (2002) An association between a missense polymorphism in the close homologue of L1 (CHL1, CALL) gene and schizophrenia. Mol Psychiatry. 7(4):412–415CrossRefPubMed Sakurai K, Migita O, Toru M, Arinami T (2002) An association between a missense polymorphism in the close homologue of L1 (CHL1, CALL) gene and schizophrenia. Mol Psychiatry. 7(4):412–415CrossRefPubMed
Zurück zum Zitat Senchenko VN, Krasnov GS, Dmitriev AA, Kudryavtseva AV, Anedchenko EA, Braga EA et al (2011) Differential expression of CHL1 gene during development of major human cancers. PLoS One 6(3):e15612CrossRefPubMedPubMedCentral Senchenko VN, Krasnov GS, Dmitriev AA, Kudryavtseva AV, Anedchenko EA, Braga EA et al (2011) Differential expression of CHL1 gene during development of major human cancers. PLoS One 6(3):e15612CrossRefPubMedPubMedCentral
Zurück zum Zitat Shen M, Ren X (2017) Highlights on immune checkpoint inhibitors in non-small cell lung cancer. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 39(3):1010428317695013CrossRef Shen M, Ren X (2017) Highlights on immune checkpoint inhibitors in non-small cell lung cancer. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 39(3):1010428317695013CrossRef
Zurück zum Zitat Siesser PF, Maness PF (2009) L1 cell adhesion molecules as regulators of tumor cell invasiveness. Cell Adhes Migr. 3(3):275–277CrossRef Siesser PF, Maness PF (2009) L1 cell adhesion molecules as regulators of tumor cell invasiveness. Cell Adhes Migr. 3(3):275–277CrossRef
Zurück zum Zitat Simon R, Mirlacher M, Sauter G (2010) Immunohistochemical analysis of tissue microarrays. Methods Mol Biol Clifton NJ. 664:113–126CrossRef Simon R, Mirlacher M, Sauter G (2010) Immunohistochemical analysis of tissue microarrays. Methods Mol Biol Clifton NJ. 664:113–126CrossRef
Zurück zum Zitat Tachezy M, Zander H, Marx AH, Gebauer F, Rawnaq T, Kaifi JT et al (2011) ALCAM (CD166) expression as novel prognostic biomarker for pancreatic neuroendocrine tumor patients. J Surg Res 170(2):226–232CrossRefPubMed Tachezy M, Zander H, Marx AH, Gebauer F, Rawnaq T, Kaifi JT et al (2011) ALCAM (CD166) expression as novel prognostic biomarker for pancreatic neuroendocrine tumor patients. J Surg Res 170(2):226–232CrossRefPubMed
Zurück zum Zitat Tang H, Jiang L, Zhu C, Liu R, Wu Y, Yan Q et al (2019) Loss of cell adhesion molecule L1 like promotes tumor growth and metastasis in esophageal squamous cell carcinoma. Oncogene 8:1CrossRef Tang H, Jiang L, Zhu C, Liu R, Wu Y, Yan Q et al (2019) Loss of cell adhesion molecule L1 like promotes tumor growth and metastasis in esophageal squamous cell carcinoma. Oncogene 8:1CrossRef
Zurück zum Zitat Tian W, Li X, Ren Y, Yin Z, Quan X, Zheng C et al (2018) CHL1 gene polymorphisms increase lung cancer susceptibility. Oncotarget. 9(17):13545–13550CrossRefPubMedPubMedCentral Tian W, Li X, Ren Y, Yin Z, Quan X, Zheng C et al (2018) CHL1 gene polymorphisms increase lung cancer susceptibility. Oncotarget. 9(17):13545–13550CrossRefPubMedPubMedCentral
Zurück zum Zitat Wei MH, Karavanova I, Ivanov SV, Popescu NC, Keck CL, Pack S et al (1998) In silico-initiated cloning and molecular characterization of a novel human member of the L1 gene family of neural cell adhesion molecules. Hum Genet 103(3):355–364CrossRefPubMed Wei MH, Karavanova I, Ivanov SV, Popescu NC, Keck CL, Pack S et al (1998) In silico-initiated cloning and molecular characterization of a novel human member of the L1 gene family of neural cell adhesion molecules. Hum Genet 103(3):355–364CrossRefPubMed
Zurück zum Zitat Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U et al (2006) Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 94(1):128–135CrossRefPubMedPubMedCentral Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U et al (2006) Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 94(1):128–135CrossRefPubMedPubMedCentral
Zurück zum Zitat Zamay TN, Zamay GS, Kolovskaya OS, Zukov RA, Petrova MM, Gargaun A et al (2017) Current and prospective protein biomarkers of lung cancer. Cancers. 9(11):155CrossRefPubMedCentral Zamay TN, Zamay GS, Kolovskaya OS, Zukov RA, Petrova MM, Gargaun A et al (2017) Current and prospective protein biomarkers of lung cancer. Cancers. 9(11):155CrossRefPubMedCentral
Zurück zum Zitat Zecchini S, Cavallaro U (2010) Neural cell adhesion molecule in cancer: expression and mechanisms. Adv Exp Med Biol 663:319–333CrossRefPubMed Zecchini S, Cavallaro U (2010) Neural cell adhesion molecule in cancer: expression and mechanisms. Adv Exp Med Biol 663:319–333CrossRefPubMed
Metadaten
Titel
Protein expression of close homologue of L1 (CHL1) is a marker for overall survival in non-small cell lung cancer (NSCLC)
verfasst von
Jenny Hötzel
Nathaniel Melling
Julia Müller
Adam Polonski
Gerrit Wolters-Eisfeld
Jakob R. Izbicki
Karl-F. Karstens
Michael Tachezy
Publikationsdatum
01.08.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 9/2019
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-019-02989-x

Weitere Artikel der Ausgabe 9/2019

Journal of Cancer Research and Clinical Oncology 9/2019 Zur Ausgabe

Neu im Fachgebiet Onkologie

Die beste Jahreszeit für eine Krebsimmuntherapie

16.07.2024 Onkologische Immuntherapie Nachrichten

Die Wirksamkeit von Checkpointhemmern scheint klinisch relevanten saisonalen Schwankungen zu unterliegen. Patienten mit fortgeschrittenem nichtkleinzelligem Lungenkarzinom etwa hatten das beste Outcome, wenn die PD-1-Inhibitor-Infusionen in den Wintermonaten starteten.

Partielle Nephrektomie: Videoanalysen zur Verbesserung der chirurgischen Qualität

16.07.2024 Nephrektomie Nachrichten

Je versierter Operateurinnen und Operateure sind, desto geringer ist das Risiko für Komplikationen. Eine kleine US-Studie spricht dafür, dass das auch bei Roboter-assistierten Nephrektomien gilt – und dass sich Op.-Videos für die Beurteilung eignen.        

S3-Leitlinie Endometriumkarzinom aktualisiert

15.07.2024 Endometriumkarzinom Nachrichten

Die angepasste Version der S3-Leitlinie Endometriumkarzinom enthält unter anderem Empfehlungen zu Risikofaktoren, wie der Hormonersatztherapie, sowie darüber, wann eine vaginale Brachytherapie und wann eine Perkutanbestrahlung angebracht ist.

Warum junge Brustkrebspatientinnen die endokrine Therapie absetzen

15.07.2024 Mammakarzinom Nachrichten

Bei jungen Brustkrebspatientinnen ist die Wahrscheinlichkeit groß, dass sie eine adjuvante endokrine Therapie vorzeitig absetzen. In einer europäischen Kohorte wurden dafür zwei Risikofaktoren identifiziert, die bei der Behandlung berücksichtigt werden sollten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.